|
2
|
EL Masri H, McGuire TM, van Driel ML, Benham H, Hollingworth SA. Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review. Patient Prefer Adherence 2022; 16:2609-2637. [PMID: 36164323 PMCID: PMC9508999 DOI: 10.2147/ppa.s375062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 08/25/2022] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND A critical gap exits in understanding the dynamics of patient-based benefit-risk assessment (BRA) of medicines in chronic diseases during the disease journey. PURPOSE To systematically review and synthesize current evidence on the changes of patients' preferences about the benefits and risks of medicines during their disease journey including the influence of disease duration and severity, and previous treatment experience. METHODS A systematic review of studies identified in PubMed and Embase, from inception to November 2020, was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. Articles were eligible if they analyzed adult patient-based BRA of medicines with a chronic disease, based on at least one of the pre-specified dimensions: disease severity, disease duration, or previous treatment experience. RESULTS A total of 26,228 articles were identified and 105 were eligible for inclusion. Of these, 85 detected a variation in patient-based BRA of medicines with at least one of the pre-specified criteria. Patients with higher disease severity and more treatment experience have increased risk tolerance. It remains inconclusive whether disease duration directly affects the relative importance of a patient's preference. CONCLUSION Factors important for patients' BRA of their medicines during a chronic disease journey vary more with their clinical situation and previous treatment experience than with time since diagnosis. Due to the importance of these factors on patients' perspectives and potential impact on their decision-making and eventually their clinical outcomes, there is a need for more studies to assess the dynamics of patients' BRA in every disease.
Collapse
Affiliation(s)
- Hiba EL Masri
- School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia
- Correspondence: Hiba EL Masri, School of Pharmacy, The University of Queensland, 20 Cornwall St, Woolloongabba, Brisbane, Queensland, 4102, Australia, Tel +61 478512234, Email
| | - Treasure M McGuire
- School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia
- Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia
- Mater Pharmacy, Mater Health, Brisbane, Queensland, Australia
| | - Mieke L van Driel
- Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Brisbane, Australia
| | - Helen Benham
- Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
- Department of Rheumatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | | |
Collapse
|
|
3
|
Kang J, Lechuga M, Braun J, Kossler A, Douglas R, Cockerham K. Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects. JOURNAL OF INFUSION NURSING 2021; 44:331-338. [PMID: 34753152 PMCID: PMC10853843 DOI: 10.1097/nan.0000000000000446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Teprotumumab was the first and only medication approved by the US Food and Drug Administration for the treatment of thyroid eye disease in January 2020. Thyroid eye disease is a complex autoimmune inflammatory disease that can be sight-threatening, debilitating, and disfiguring to affected patients. Although biologic therapies are a preferred treatment option for many complex immunologic and oncologic conditions, their use in ophthalmology and endocrinology may be more novel. The goals of this article are to introduce this new therapeutic option; discuss its mechanism of action, indications for use, administration protocol, infusion precautions, and informed consent; and review common side effects and management.
Collapse
Affiliation(s)
- Julia Kang
- Central Valley Eye Medical Group; Stockton, California (Drs Kang and Cockerham); Private Practice, Beverly Hills, California (Mss Lechuga and Braun and Dr Douglas); Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California (Drs Kossler and Cockerham)
- Julia Kang, MD, MPH, is a board-certified ophthalmologist who completed her residency training at the Emory Eye Center. She is currently in fellowship training for oculoplastic and reconstructive surgery. She has coauthored multiple peer-reviewed publications and, as an artist, she has contributed medical illustrations for oculoplastic surgery book chapters. After fellowship training, she will be returning to Atlanta, Georgia, to join a private practice group
- Maria Lechuga, BSN, RN, has been a registered nurse and an infusion nurse for more than a decade. She has been running Dr Raymond Douglas's infusion center for the past 2 years. She is currently pursuing her nurse practitioner education and certification
- Jenna Braun, BS, is a clinical research coordinator for Raymond Douglas, MD, PhD. She received her Bachelor of Science degree in neurobiology at the University of Wisconsin and has worked as a clinical research coordinator for 1 year
- Andrea Kossler, MD, is a board-certified ophthalmologist with fellowship training in orbital disease and oculoplastic reconstruction. She has been caring for thyroid eye disease patients for more than a decade. She is an assistant professor in the Stanford Department of Ophthalmology. She has published more than 100 peer-reviewed articles and lectures on thyroid eye disease nationally and internationally
- Raymond Douglas, MD, PhD, is an experienced board-certified aesthetic and reconstructive oculoplastic specialist. Patients with thyroid eye disease, Graves' eye disease, previous unsuccessful surgery, cancers of the eyelids or face, and trauma-induced injuries seek Dr Douglas's expert, customized care at both his primary practice in Beverly Hills and international practice, LA Face, in Shanghai, China. His expertise in treating difficult cases of disfigurement attributed to thyroid-associated eye diseases and cosmetic and reconstruction surgeries has made him a highly respected educational and surgical authority for both reconstructive and cosmetics arts of facial plastics
- Kimberly Cockerham, MD, FACS, is a board-certified ophthalmologist with fellowship training in neuro-ophthalmology, orbital disease, and oculoplastic reconstruction. She has been caring for patients with thyroid eye disease for several decades. She is currently an adjunct clinical associate professor in the Stanford Department of Ophthalmology. Dr Cockerham was previously chief of orbital disease and oculoplastic surgery at University of California San Francisco and Walter Reed Army Medical Center. She has published more than 100 peer-reviewed articles, coauthored a book on orbital disease diagnosis and management, and lectures on thyroid eye disease nationally and internationally
| | - Maria Lechuga
- Central Valley Eye Medical Group; Stockton, California (Drs Kang and Cockerham); Private Practice, Beverly Hills, California (Mss Lechuga and Braun and Dr Douglas); Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California (Drs Kossler and Cockerham)
- Julia Kang, MD, MPH, is a board-certified ophthalmologist who completed her residency training at the Emory Eye Center. She is currently in fellowship training for oculoplastic and reconstructive surgery. She has coauthored multiple peer-reviewed publications and, as an artist, she has contributed medical illustrations for oculoplastic surgery book chapters. After fellowship training, she will be returning to Atlanta, Georgia, to join a private practice group
- Maria Lechuga, BSN, RN, has been a registered nurse and an infusion nurse for more than a decade. She has been running Dr Raymond Douglas's infusion center for the past 2 years. She is currently pursuing her nurse practitioner education and certification
- Jenna Braun, BS, is a clinical research coordinator for Raymond Douglas, MD, PhD. She received her Bachelor of Science degree in neurobiology at the University of Wisconsin and has worked as a clinical research coordinator for 1 year
- Andrea Kossler, MD, is a board-certified ophthalmologist with fellowship training in orbital disease and oculoplastic reconstruction. She has been caring for thyroid eye disease patients for more than a decade. She is an assistant professor in the Stanford Department of Ophthalmology. She has published more than 100 peer-reviewed articles and lectures on thyroid eye disease nationally and internationally
- Raymond Douglas, MD, PhD, is an experienced board-certified aesthetic and reconstructive oculoplastic specialist. Patients with thyroid eye disease, Graves' eye disease, previous unsuccessful surgery, cancers of the eyelids or face, and trauma-induced injuries seek Dr Douglas's expert, customized care at both his primary practice in Beverly Hills and international practice, LA Face, in Shanghai, China. His expertise in treating difficult cases of disfigurement attributed to thyroid-associated eye diseases and cosmetic and reconstruction surgeries has made him a highly respected educational and surgical authority for both reconstructive and cosmetics arts of facial plastics
- Kimberly Cockerham, MD, FACS, is a board-certified ophthalmologist with fellowship training in neuro-ophthalmology, orbital disease, and oculoplastic reconstruction. She has been caring for patients with thyroid eye disease for several decades. She is currently an adjunct clinical associate professor in the Stanford Department of Ophthalmology. Dr Cockerham was previously chief of orbital disease and oculoplastic surgery at University of California San Francisco and Walter Reed Army Medical Center. She has published more than 100 peer-reviewed articles, coauthored a book on orbital disease diagnosis and management, and lectures on thyroid eye disease nationally and internationally
| | - Jenna Braun
- Central Valley Eye Medical Group; Stockton, California (Drs Kang and Cockerham); Private Practice, Beverly Hills, California (Mss Lechuga and Braun and Dr Douglas); Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California (Drs Kossler and Cockerham)
- Julia Kang, MD, MPH, is a board-certified ophthalmologist who completed her residency training at the Emory Eye Center. She is currently in fellowship training for oculoplastic and reconstructive surgery. She has coauthored multiple peer-reviewed publications and, as an artist, she has contributed medical illustrations for oculoplastic surgery book chapters. After fellowship training, she will be returning to Atlanta, Georgia, to join a private practice group
- Maria Lechuga, BSN, RN, has been a registered nurse and an infusion nurse for more than a decade. She has been running Dr Raymond Douglas's infusion center for the past 2 years. She is currently pursuing her nurse practitioner education and certification
- Jenna Braun, BS, is a clinical research coordinator for Raymond Douglas, MD, PhD. She received her Bachelor of Science degree in neurobiology at the University of Wisconsin and has worked as a clinical research coordinator for 1 year
- Andrea Kossler, MD, is a board-certified ophthalmologist with fellowship training in orbital disease and oculoplastic reconstruction. She has been caring for thyroid eye disease patients for more than a decade. She is an assistant professor in the Stanford Department of Ophthalmology. She has published more than 100 peer-reviewed articles and lectures on thyroid eye disease nationally and internationally
- Raymond Douglas, MD, PhD, is an experienced board-certified aesthetic and reconstructive oculoplastic specialist. Patients with thyroid eye disease, Graves' eye disease, previous unsuccessful surgery, cancers of the eyelids or face, and trauma-induced injuries seek Dr Douglas's expert, customized care at both his primary practice in Beverly Hills and international practice, LA Face, in Shanghai, China. His expertise in treating difficult cases of disfigurement attributed to thyroid-associated eye diseases and cosmetic and reconstruction surgeries has made him a highly respected educational and surgical authority for both reconstructive and cosmetics arts of facial plastics
- Kimberly Cockerham, MD, FACS, is a board-certified ophthalmologist with fellowship training in neuro-ophthalmology, orbital disease, and oculoplastic reconstruction. She has been caring for patients with thyroid eye disease for several decades. She is currently an adjunct clinical associate professor in the Stanford Department of Ophthalmology. Dr Cockerham was previously chief of orbital disease and oculoplastic surgery at University of California San Francisco and Walter Reed Army Medical Center. She has published more than 100 peer-reviewed articles, coauthored a book on orbital disease diagnosis and management, and lectures on thyroid eye disease nationally and internationally
| | - Andrea Kossler
- Central Valley Eye Medical Group; Stockton, California (Drs Kang and Cockerham); Private Practice, Beverly Hills, California (Mss Lechuga and Braun and Dr Douglas); Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California (Drs Kossler and Cockerham)
- Julia Kang, MD, MPH, is a board-certified ophthalmologist who completed her residency training at the Emory Eye Center. She is currently in fellowship training for oculoplastic and reconstructive surgery. She has coauthored multiple peer-reviewed publications and, as an artist, she has contributed medical illustrations for oculoplastic surgery book chapters. After fellowship training, she will be returning to Atlanta, Georgia, to join a private practice group
- Maria Lechuga, BSN, RN, has been a registered nurse and an infusion nurse for more than a decade. She has been running Dr Raymond Douglas's infusion center for the past 2 years. She is currently pursuing her nurse practitioner education and certification
- Jenna Braun, BS, is a clinical research coordinator for Raymond Douglas, MD, PhD. She received her Bachelor of Science degree in neurobiology at the University of Wisconsin and has worked as a clinical research coordinator for 1 year
- Andrea Kossler, MD, is a board-certified ophthalmologist with fellowship training in orbital disease and oculoplastic reconstruction. She has been caring for thyroid eye disease patients for more than a decade. She is an assistant professor in the Stanford Department of Ophthalmology. She has published more than 100 peer-reviewed articles and lectures on thyroid eye disease nationally and internationally
- Raymond Douglas, MD, PhD, is an experienced board-certified aesthetic and reconstructive oculoplastic specialist. Patients with thyroid eye disease, Graves' eye disease, previous unsuccessful surgery, cancers of the eyelids or face, and trauma-induced injuries seek Dr Douglas's expert, customized care at both his primary practice in Beverly Hills and international practice, LA Face, in Shanghai, China. His expertise in treating difficult cases of disfigurement attributed to thyroid-associated eye diseases and cosmetic and reconstruction surgeries has made him a highly respected educational and surgical authority for both reconstructive and cosmetics arts of facial plastics
- Kimberly Cockerham, MD, FACS, is a board-certified ophthalmologist with fellowship training in neuro-ophthalmology, orbital disease, and oculoplastic reconstruction. She has been caring for patients with thyroid eye disease for several decades. She is currently an adjunct clinical associate professor in the Stanford Department of Ophthalmology. Dr Cockerham was previously chief of orbital disease and oculoplastic surgery at University of California San Francisco and Walter Reed Army Medical Center. She has published more than 100 peer-reviewed articles, coauthored a book on orbital disease diagnosis and management, and lectures on thyroid eye disease nationally and internationally
| | - Raymond Douglas
- Central Valley Eye Medical Group; Stockton, California (Drs Kang and Cockerham); Private Practice, Beverly Hills, California (Mss Lechuga and Braun and Dr Douglas); Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California (Drs Kossler and Cockerham)
- Julia Kang, MD, MPH, is a board-certified ophthalmologist who completed her residency training at the Emory Eye Center. She is currently in fellowship training for oculoplastic and reconstructive surgery. She has coauthored multiple peer-reviewed publications and, as an artist, she has contributed medical illustrations for oculoplastic surgery book chapters. After fellowship training, she will be returning to Atlanta, Georgia, to join a private practice group
- Maria Lechuga, BSN, RN, has been a registered nurse and an infusion nurse for more than a decade. She has been running Dr Raymond Douglas's infusion center for the past 2 years. She is currently pursuing her nurse practitioner education and certification
- Jenna Braun, BS, is a clinical research coordinator for Raymond Douglas, MD, PhD. She received her Bachelor of Science degree in neurobiology at the University of Wisconsin and has worked as a clinical research coordinator for 1 year
- Andrea Kossler, MD, is a board-certified ophthalmologist with fellowship training in orbital disease and oculoplastic reconstruction. She has been caring for thyroid eye disease patients for more than a decade. She is an assistant professor in the Stanford Department of Ophthalmology. She has published more than 100 peer-reviewed articles and lectures on thyroid eye disease nationally and internationally
- Raymond Douglas, MD, PhD, is an experienced board-certified aesthetic and reconstructive oculoplastic specialist. Patients with thyroid eye disease, Graves' eye disease, previous unsuccessful surgery, cancers of the eyelids or face, and trauma-induced injuries seek Dr Douglas's expert, customized care at both his primary practice in Beverly Hills and international practice, LA Face, in Shanghai, China. His expertise in treating difficult cases of disfigurement attributed to thyroid-associated eye diseases and cosmetic and reconstruction surgeries has made him a highly respected educational and surgical authority for both reconstructive and cosmetics arts of facial plastics
- Kimberly Cockerham, MD, FACS, is a board-certified ophthalmologist with fellowship training in neuro-ophthalmology, orbital disease, and oculoplastic reconstruction. She has been caring for patients with thyroid eye disease for several decades. She is currently an adjunct clinical associate professor in the Stanford Department of Ophthalmology. Dr Cockerham was previously chief of orbital disease and oculoplastic surgery at University of California San Francisco and Walter Reed Army Medical Center. She has published more than 100 peer-reviewed articles, coauthored a book on orbital disease diagnosis and management, and lectures on thyroid eye disease nationally and internationally
| | - Kimberly Cockerham
- Central Valley Eye Medical Group; Stockton, California (Drs Kang and Cockerham); Private Practice, Beverly Hills, California (Mss Lechuga and Braun and Dr Douglas); Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California (Drs Kossler and Cockerham)
- Julia Kang, MD, MPH, is a board-certified ophthalmologist who completed her residency training at the Emory Eye Center. She is currently in fellowship training for oculoplastic and reconstructive surgery. She has coauthored multiple peer-reviewed publications and, as an artist, she has contributed medical illustrations for oculoplastic surgery book chapters. After fellowship training, she will be returning to Atlanta, Georgia, to join a private practice group
- Maria Lechuga, BSN, RN, has been a registered nurse and an infusion nurse for more than a decade. She has been running Dr Raymond Douglas's infusion center for the past 2 years. She is currently pursuing her nurse practitioner education and certification
- Jenna Braun, BS, is a clinical research coordinator for Raymond Douglas, MD, PhD. She received her Bachelor of Science degree in neurobiology at the University of Wisconsin and has worked as a clinical research coordinator for 1 year
- Andrea Kossler, MD, is a board-certified ophthalmologist with fellowship training in orbital disease and oculoplastic reconstruction. She has been caring for thyroid eye disease patients for more than a decade. She is an assistant professor in the Stanford Department of Ophthalmology. She has published more than 100 peer-reviewed articles and lectures on thyroid eye disease nationally and internationally
- Raymond Douglas, MD, PhD, is an experienced board-certified aesthetic and reconstructive oculoplastic specialist. Patients with thyroid eye disease, Graves' eye disease, previous unsuccessful surgery, cancers of the eyelids or face, and trauma-induced injuries seek Dr Douglas's expert, customized care at both his primary practice in Beverly Hills and international practice, LA Face, in Shanghai, China. His expertise in treating difficult cases of disfigurement attributed to thyroid-associated eye diseases and cosmetic and reconstruction surgeries has made him a highly respected educational and surgical authority for both reconstructive and cosmetics arts of facial plastics
- Kimberly Cockerham, MD, FACS, is a board-certified ophthalmologist with fellowship training in neuro-ophthalmology, orbital disease, and oculoplastic reconstruction. She has been caring for patients with thyroid eye disease for several decades. She is currently an adjunct clinical associate professor in the Stanford Department of Ophthalmology. Dr Cockerham was previously chief of orbital disease and oculoplastic surgery at University of California San Francisco and Walter Reed Army Medical Center. She has published more than 100 peer-reviewed articles, coauthored a book on orbital disease diagnosis and management, and lectures on thyroid eye disease nationally and internationally
| |
Collapse
|
|
4
|
Choi IA, Kim JH, Hae Chang S, Song R, Ha YJ, Won Kim H, Seok Lee J, Choi B, Oh YJ, Moon KW. Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea. Arch Rheumatol 2021; 36:499-509. [PMID: 35382362 PMCID: PMC8957778 DOI: 10.46497/archrheumatol.2021.8524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 12/11/2020] [Indexed: 12/24/2022] Open
Abstract
Objectives: The aim of this study was to evaluate the patient’s perception of the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) and provide a basis for physicians to understand the patient’s perspective.
Patients and methods: Between December 2018 and June 2019, a total of 307 patients (162 males, 145 females; mean age: 48 years; range, 18 to 81 years) were included in this investigator-initiated, multi-center, observational, and cross-sectional study in six rheumatology centers. We asked patients using bDMARDs to treat rheumatoid arthritis (RA) or ankylosing spondylitis (AS) to complete a questionnaire regarding major considerations and satisfaction with bDMARDs, preferred administration route, knowledge about bDMARDs, experiences of adverse events, non-adherence, and expectations of their healthcare provider. The satisfaction of physician and clinical information on the patient's disease and treatment were also collected.
Results: Of the patients, 139 had RA and 168 had AS. Median disease duration was six years in RA and five years in AS. A total of 80.1% of the patients and 77.1% of the physicians indicated being satisfied or very satisfied with the therapeutic effect of the current bDMARD. Most patients were open to intravenous or subcutaneous injection, with the most preferred route of administration being subcutaneous (41.3%), followed by intravenous (32.0%), and oral (26.7%). The patients considered therapeutic effect to be more important than cost or convenience while choosing a bDMARD (69.3%), and most were willing to be educated about therapeutic effects (46.1%). Only 35.2% of the patients reported well and/or very well knowledge about the therapeutic effects, side effects, and administration methods of their current bDMARD, and 86.6% cited their physician as the primary source of information about biological treatment.
Conclusion: Patients value therapeutic effect more than cost or convenience while selecting a bDMARD, and consider their physicians to be the primary information source. Therefore, it is important for physicians to provide appropriate education and encourage patients to cooperate actively with treatment.
Collapse
Affiliation(s)
- In Ah Choi
- Department of Internal Medicine, Division of Rheumatology, Chungbuk National University Hospital, Cheongju, South Korea
- Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongu, South Korea
| | - Ji Hyoun Kim
- Department of Internal Medicine, Division of Rheumatology, Chungbuk National University Hospital, Cheongju, South Korea
| | - Sung Hae Chang
- Department of Internal Medicine, Division of Rheumatology, Soonchunhyang University Hospital, Cheonan, South Korea
| | - Ran Song
- Department of Internal Medicine, Division of Rheumatology, Kyung Hee University, Seoul, South Korea
| | - You-Jung Ha
- Department of Internal Medicine, Division of Rheumatology, Seoul National University Bundang Hospital, Seongnam, South Korea
| | - Hye Won Kim
- Department of Internal Medicine, Hospital Medicine Center, Seoul National University Bundang Hospital, Seongnam, South Korea
| | - Jeong Seok Lee
- Korea Advanced Institute of Science and Technology, Graduate School of Medical Science and Engineering, Daejeon, South Korea
| | - Byoongyong Choi
- Department of Internal Medicine, Division of Rheumatology, Seoul Metropolitan Seoul Medical Center, Seoul, South Korea
| | - Yoon-Jeong Oh
- Department of Internal Medicine, Division of Rheumatology, Kangwon National University School of Medicine, Chuncheon, South Korea
| | - Ki Won Moon
- Department of Internal Medicine, Division of Rheumatology, Kangwon National University School of Medicine, Chuncheon, South Korea
| |
Collapse
|
|
5
|
Leung K, Jackson CS, Hammami MB. Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease. CROHN'S & COLITIS 360 2021; 3:otab025. [PMID: 36776658 PMCID: PMC9802361 DOI: 10.1093/crocol/otab025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Lay Summary
Many medications used to treat inflammatory bowel disease (IBD) can increase the risk of infection and cancer, particularly in elderly patients. This study found that vedolizumab, a targeted therapy, was effective and safe in elderly patients with IBD.
Collapse
Affiliation(s)
- Kenneth Leung
- Department of Medicine, University of California, Riverside, Riverside, California, USA,Division of Gastroenterology and Hepatology, VA Loma Linda Health Care System, Loma Linda, California, USA,Address correspondence to: Kenneth Leung, MD, University of California, Riverside School of Medicine, SOM Education Building, 900 University Avenue, Riverside, CA 92521, USA ()
| | - Christian S Jackson
- Department of Medicine, University of California, Riverside, Riverside, California, USA,Division of Gastroenterology and Hepatology, VA Loma Linda Health Care System, Loma Linda, California, USA
| | - Muhammad Bader Hammami
- Department of Medicine, University of California, Riverside, Riverside, California, USA,Division of Gastroenterology and Hepatology, VA Loma Linda Health Care System, Loma Linda, California, USA
| |
Collapse
|
|
8
|
Singh JA, Tornberg H, Goodman SM. Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis. Joint Bone Spine 2020; 88:105053. [PMID: 32681975 DOI: 10.1016/j.jbspin.2020.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 07/01/2020] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To assess how patients with rheumatoid arthritis (RA) decide whether to add oral disease-modifying anti-rheumatic drugs (DMARDs) versus injectable biologic DMARDs when methotrexate response is inadequate. METHODS Using nominal group technique (NGT), RA patients answered the question "What sort of things are important to you when you make a decision between adding pills versus injectable medications to treat rheumatoid arthritis when methotrexate fails to control RA disease activity?" Patients nominated, discussed, and voted for the responses. RESULTS Forty-seven RA patients participated: Birmingham (n=6 NG; 21 patients) and New York City (n=4 NG; 26 patients). They were predominantly female (85%), 70% white, with a mean age of 64.5 years and 58% had>10-year RA duration. Present/past DMARDs included methotrexate only in 6%, other traditional DMARDs in 15%, glucocorticoids in combination with traditional DMARDs in 11%, and biologics and/or Jak-kinase inhibitors in 68% of participants. Voted domains in order were: (1) efficacy/effectiveness and the onset/mode of action (78/282 votes); (2) side effects/fear of side effects (84/282 votes); (3) cost including out of pocket, co-payments and patient responsibility (54/282 votes); (4) convenience/frequency of use (27/282 votes); (5) doctor's opinion (20/282 votes); (6) other drugs/comorbidity/other patient's experience/effects on other people (3/282 votes); (7) fear of needles (8/282 votes); and (8) newness of the medication (8/282 votes). CONCLUSIONS We identified the patient perspective regarding the choice between adding oral versus injectable DMARD once methotrexate failed to control RA disease activity. This knowledge can help in shared decision-making for DMARD choice in RA treatment.
Collapse
Affiliation(s)
- Jasvinder A Singh
- Birmingham Veterans Affairs (VA) Medical Center, 700 19th St S, Birmingham, AL, USA; Department of Medicine at the School of Medicine, University of Alabama, 510 20th Street S, Birmingham, 35294, AL, USA; Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, 1665 University Blvd, Birmingham, 35233, Birmingham, AL, USA; Department of Medicine, Hospital for Special Surgery, 535 E 70th Street, 10021 NY, NY, USA.
| | - Haley Tornberg
- Department of Medicine, Hospital for Special Surgery, 535 E 70th Street, 10021 NY, NY, USA
| | - Susan M Goodman
- Department of Medicine, Hospital for Special Surgery, 535 E 70th Street, 10021 NY, NY, USA
| |
Collapse
|